Back to top

gene-therapy: Archive

Sundeep Ganoria

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?

The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change

Zacks Equity Research

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change